Retina

Daraius Shroff, MD, developed the Triple S toolkit for hAM grafting for use during vitreoretinal surgery, which he described at the 2023 Vit-Buckle Annual Society meeting.

J. Peter Campbell, MD, MPH, sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss pediatric retina surgery and 3 key pearls to consider while performing the surgery.

Patients and employees, past and present, have had personal and protected health information acquired without authorization.

According to National Eye Institute researchers, the variants generate malformed proteins that alter the stability of the membrane attack complex, which may drive a chronic inflammatory response in the retina.

By crossing into the retina, investigators have uncovered a new DHA supplement achieves what previous ones could not.

Retinal redetachment can occur frequently in eyes that underwent repair of rhegmatogenous retinal detachments (RRDs) after infectious endophthalmitis.

According to National Eye Institute researchers, the strategy may speed the delivery of therapeutic options relative to time it would take to develop gene therapies.

According to the company, clinically meaningful visual acuity gains were observed in several MCO-010 treated patients. The trial also demonstrated a favorable safety profile for MCO-010 with no serious or severe adverse events.

Researchers at Buck Institute, working with Google Health and Zuckerberg San Francisco General Hospital, are studying the eye as a window into human aging.

According to researchers at UCLA, “dormant” cone photoreceptors might continue to drive retinal activity for vision.

Nitish Mehta, MD discusses the latest trends in Artificial Intelligence and Machine Learning technology in retinal imaging and its uses for ophthalmologists.

Learning more about the early AD stages, when brain damage is limited, should allow early and more efficacious treatment, and improvements in imaging may be able to pick up changes earlier.

According to researchers, diabetes mellitus is caused by higher levels of blood glucose due to the lack of production of insulin by the body, resistance to insulin, or both.

This subtype of artificial intelligence technology may have long-range implications for clinical trials.

According to the company, the funding supports the Phase 2 clinical study of ONL1204 ophthalmic solution to evaluate the safety and efficacy in patients diagnosed with macula-off rhegmatogenous retinal detachment.

Researchers conducted a retrospective analysis of longitudinal, clinical data from patients with high myopic MNV treated with intravitreal bevacizumab.

According to researchers, patients with chronic CSC treated with 1 fovea-involving, half-dose PTD application had a significant improvement in structure and function at the final follow-up and foveal atrophy did not develop in any patients.

Primary vitreoretinal lymphoma is a rare, aggressive, and potentially fatal retinal cancer that is diagnosed in approximately 300 to 600 patients in the United States per year.

Despite its promise, RGC replacement represents a more formidable challenge.

Artificial intelligence (AI) with ultra-widefield fundus autofluorescence images may be helpful to objectively estimate progression of retinitis pigmentosa (RP) and visual function.

Yusuke Oshima, MD, PhD, in a presentation at the 38th Asia-Pacific Academy of Ophthalmology Congress, Kuala Lumpur, Malaysia, discussed the advantages of using a beveled-tip ultra-speed probe for complete vitreous shaving during retinal detachment vitrectomies.

Analysis of data from the pooled Tenaya and Lucerne studies showed the faricimab achieved greater anatomic improvements compared to aflibercept during the matched-dosing period.

Arun Singh, MD, discusses Retinoblastoma in 2023 and the advancements of tumor chemotherapy from his presentation at the Asia-Pacific Academy of Ophthalmology (APAO) 2023 conference.

The considerations for biosimilars in clinical practice are interesting and remain to be determined, according to George A. Williams, MD.

Apellis received FDA approval for intravitreal pegcetacoplan (SYFOVRE) to treat geographic atrophy secondary to AMD. This news follows the submission of the 24-month phase 3 data in November 2022.

Carolyn Majcher, OD, FAAO, and Rishi Singh, MD, discuss new and upcoming clinical trials, investigational therapies, and diagnostic tools for the treatment of diabetic retinopathy and diabetic macular edema (DR/DME).

Diabetic retinal disease experts discuss different approaches that can reduce the treatment burden while maintaining good visual outcomes during diabetic retinopathy and diabetic macular edema (DR/DME) therapy.

Rishi Singh, MD, provides an overview of the various treatment options available for diabetic retinopathy and diabetic macular edema (DR/DME).

The company announced a PDUFA goal date of Aug. 19, 2023. The FDA has not identified any potential review issues and is not currently planning to hold an Advisory Committee meeting for avacincaptad pegol.

Three of Frontera’s gene therapy product candidates have entered clinical trials since the beginning of the year.